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ISSObjective: The role of innate immunity in the pathogenesis of cryptococcal meningitis
is unclear. We hypothesized that natural killer (NK) cell and monocyte responses show
central nervous system (CNS) compartment-specific profiles, and are altered by anti-
fungal therapy and combination antiretroviral therapy (cART) during cryptococcal
meningitis/HIV coinfection.
Design: Substudy of a prospective cohort study of adults with cryptococcal meningitis/
HIV coinfection in Durban, South Africa.
Methods: We used multiparametric flow cytometry to study compartmentalization of
subsets, CD69 (a marker of activation), CXCR3 and CX3CR1 expression, and cytokine
secretion of NK cells and monocytes in freshly collected blood and cerebrospinal fluid
(CSF) at diagnosis (n¼23), completion of antifungal therapy induction (n¼19), and
after a further 4 weeks of cART (n¼9).
Results: Relative to blood, CSF was enriched with CD56bright (immunoregulatory) NK
cells (P¼0.0004). At enrolment, CXCR3 expression was more frequent among blood
CD56bright than either blood CD56dim (P<0.0001) or CSF CD56bright (P¼0.0002) NK
cells. Antifungal therapy diminished blood (P<0.05), but not CSF CXCR3pos NK-cell
proportions nor CX3CR1pos NK-cell proportions. CD56bright and CD56dim NK cells
were more activated in CSF than blood (P<0.0001). Antifungal therapy induction
reduced CD56dim NK-cell activation in CSF (P¼0.02). Activation of blood CD56bright
and CD56dim NK cells was diminished following cART commencement (P<0.0001,
P¼0.03). Immunoregulatory NK cells in CSF tended to secrete higher levels
of CXCL10 (P¼0.06) and lower levels of tumor necrosis factor a (P¼0.06) than
blood immunoregulatory NK cells. CSF was enriched with nonclassical monocytes
(P¼0.001), but antifungal therapy restored proportions of classical monocytes
(P¼0.007).
Conclusion: These results highlight CNS activation, trafficking, and function of NK
cells and monocytes in cryptococcal meningitis/HIV and implicate immunoregulatoryippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
DS Programme of Research in South Africa, bHIV Pathogenesis Programme, Nelson R Mandela School of
ity of KwaZulu Natal, Durban, South Africa, cNuffield Department of Medicine, University of Oxford, Oxford,
of Infectious Diseases, Monash University and Alfred Hospital, eCentre for Biomedical Research, Burnet
ne, fSchool of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia,
fectious Diseases, Nelson R Mandela School of Medicine, hKwaZulu-Natal Research Institute for Tuberculosis
University of KwaZulu Natal, Durban, South Africa, iMax Planck Institute for Infection Biology, Berlin,
edgar Evers College (City University of New York), Brooklyn, New York, USA.
o Vivek Naranbhai, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
ell.ox.ac.uk
i and Christina C. Chang contributed equally to the writing of the article.
ember 2013; revised: 6 January 2014; accepted: 6 January 2014.
.0000000000000200
N 0269-9370 Q 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins 657
Copyright © Lip
658 AIDS 2014, Vol 28 No 5NK cells and proinflammatory monocytes as potential modulators of cryptococcal
meningitis pathogenesis during HIV coinfection.
 2014 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2014, 28:657–666Keywords: cerebrospinal fluid, cryptococcal meningitis, HIV-1, monocytes,
natural killer cellsIntroduction
Cryptococcal meningitis is a major cause of morbidity
and mortality in patients with HIV and AIDS.
Annually, approximately 957 900 cases of cryptococcal
meningitis occur, resulting in 624 700 deaths by
3 months after infection, with sub-Saharan Africa
bearing the largest burden of disease [1]. The
underlying mechanisms causing death and disability
include development of persistently high intracranial
pressures, vasculopathies, and local brain inflammation
with bystander neuronal damage. Both innate and
adaptive immune responses contribute to the immu-
nopathogenesis of cryptococcal meningitis, but the
regulation and timing of their development remain
poorly understood.
Natural killer (NK) cells are key effectors of innate
immunity that are able to mediate pathogen elimination
by direct killing or modulating innate and adaptive
immune responses through secretion of cytokines. In
humans, expression of CD56, but a lack of CD3, CD14,
and CD19, defines their phenotype. Functionally, they
can be further subdivided into subsets with primarily
cytokine-secretion capabilities (CD56brightCD16neg) or
cytolytic capabilities (CD56dimCD16pos) [2]. Typically,
CD56bright NK cells are enriched at extravascular sites
[2]. During HIV disease, a third subset, CD56neg
CD16pos, increases disproportionately in blood, but this
subset is deficient in both cytokine production and
cytolysis [3]. In-vivo mouse and in-vitro human studies
suggest that NK cells are able to directly kill cryptococci
by perforin-mediated cytotoxicity [4,5], or indirectly
by the potentiation of macrophage antifungal activity
[6]. NK cells are able to enter the central nervous
system (CNS) during inflammatory disease such as
multiple sclerosis (MS) [7]; indeed, they have been
shown to play a major role in a variety of CNS
infections [8]. Therefore, it is plausible that in vivo, NK
cells may traffic to the site of cryptococcal infection and
exert antifungal activity. Alternatively, NK cells may
secrete immunoregulatory cytokines that affect recruit-
ment and function of other innate and adaptive immune
cells. The phenotype, function, and mechanisms of
NK-cell infiltration/trafficking into the CNS are not
well described in cryptococcal meningitis/HIV coin-
fection, and have only recently been examined in HIVpincott Williams & Wilkins. Unauthomonoinfection [9]. Thus, delineating the profiles of NK
cells in the cerebrospinal fluid (CSF) during treated
cryptococcal meningitis may allow identification of
parameters that play a role in cryptococcal meningitis/
HIV pathogenesis.
Monocytes/macrophages are a second innate immune
leukocyte subset that play a role in the pathogenesis
of some inflammatory CNS diseases, and with which
NK cells have substantial cross-talk. NK cells are
required for monocyte differentiation into dendritic
cells in several inflammatory disorders [10]. Conversely,
monocytes/macrophages are able to activate NK cells
through their secretion of proinflammatory cytokines,
interleukin-12 (IL-12) and IL-18 [11]. Monocytes
can be divided into three functionally distinct subsets
based on their relative expression of CD16 and CD14
(i.e. classical: CD14þþCD16; intermediate: CD14þþ
CD16þ; and nonclassical: CD14þCD16þþ) [12]. Among
these subsets, the nonclassical monocytes have the
greatest capacity for secreting proinflammatory cyto-
kines, such as tumor necrosis factor a (TNF-a) [13],
intermediate monocytes have superior reactive-oxygen
species production, and classical monocytes appear to
have superior phagocytic function [12]. The role of
monocytes in cryptococcal meningitis pathogenesis is
unresolved; some reports suggest that monocytes may
act as a ‘Trojan horse’ allowing entry of intracellular
cryptococci into the CNS [14], whereas others suggest
that monocytes may mediate cryptococcal elimination
[15]. Similar to other infections by intracellular pathogen
disorders, in cryptococcal meningitis, monocytes are
likely required for pathogen elimination, but also to
harbor pathogens intracellularly and impose clinically
relevant immunopathology with their activity in crypto-
coccal meningitis [16].
Here we aimed to identify changes in the innate immune
response in blood and CSF in patients with cryptococcal
meningitis and HIV in South Africa. We prospectively
characterized blood and CSF NK-cell phenotypes,
monocyte subsets and, to a lesser extent, NK-cell
function in patients with HIV/cryptococcal meningitis
coinfection at admission for care, after induction of
antifungal therapy, and after a further 4 weeks following
commencement of combination antiretroviral therapy
(cART) in some patients.rized reproduction of this article is prohibited.
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This study was conducted as a substudy of the
Cryptococcal Immune Restoration Disease (IRD) study,
which has been described previously [17]. We prospec-
tively enrolled consenting cART-naive, HIV-infected
adults with a first episode of microbiologically confirmed
cryptococcal meningitis at the King Edward VIII
Hospital in Durban, South Africa. Briefly, whole blood
and CSF were obtained at enrolment (median 2 days
after diagnosis, range 0–8 days) from 23 participants.
Amphotericin B was commenced immediately on
diagnosis for a protocolled time of 14 days. About half
of all patients had persistent cryptococcal growth after
amphotericin B therapy [17]. Following this induction
period of antifungal therapy, 19 patients were re-sampled
for blood and CSF (median 14 days after diagnosis, range
10–15 days) and were commenced on cART as per
contemporary guidelines [18] and continued on oral
fluconazole. After 4 weeks of cART, a final whole blood
specimen was obtained from a subset of nine patients
based on their availability. Serial therapeutic lumbar
punctures were conducted as required for therapeutic
purposes while continuing antifungal therapy.
At enrolment, the mean age of participants in this
substudy was 34.7 years (range 21–55 years), and 43%
were women, similar to the overall cohort [17]. The
median baseline CD4þ T-cell count was 22 cells/ml
(interquartile range, IQR 6.5–43), and the median
plasma HIV viral load was 3.18 log10 copies/ml (IQR
1.14–5.95). After 4 weeks of cART, among nine
participants from whom blood samples were available,
the median CD4þT-cell count was 74 cells/ml (IQR 49–
153), and the median plasma HIV viral load was
2.56 log10 copies/ml (IQR 2.31–2.91).
This study was approved by the University of KwaZulu-
Natal Biomedical Research Ethics Committee, the
Monash University ethics committee, and the University
of Western Australia ethics committee.
Flow cytometry analyses
The cellular profile of CSF can be taken as a measure of
cells in an intermediate compartment between blood and
CNS parenchyma. We used methods that have been
previously used to study CSF T-cell profiles in healthy
and HIV-infected patients to characterize NK cells and
monocytes in the CNS [19–21]. Peripheral blood and
CSF leukocytes were simultaneously stained with a panel
of fluorophore-conjugated antibodies and subjected
to multiparametric flow cytometry using conventional
methods. Briefly, for whole blood staining, 150 ml
undiluted whole blood collected in tubes containing
ethylenediaminotetraacetic acid (EDTA) was incubated
with the following antibodies for 20 min at 48C: anti-
CD3 APC, anti-CD8 Qdot 655, anti-CD14 Pacific
Orange (PO), anti-CD16 Pacific Blue (PB), anti-CD45Copyright © Lippincott Williams & Wilkins. UnautAlexaFluor700 (AF700), anti-CD56 PC7 (Beckman
Coulter, Pasadena, California, USA), anti-CD69 FITC,
anti-CX3CR1 PE, and anti-CXCR3 PerCP-Cy5.5. All
antibodies were from Becton Dickinson (Franklin Lakes,
New Jersey, USA), unless otherwise indicated. Red blood
cells were lysed with VersaLyse (Beckman Coulter) as per
the manufacturer’s directions, leacocytes were pelleted
by centrifugation, and fixed with a paraformaldehyde-
containing fixative (Reagent A; Life Technologies,
Carlsbad, California, USA). For CSF cell staining, the
total volume of CSF obtained from the patient (ranging
from 3 to 30 ml) was centrifuged at 750g for 10 min,
resuspended in 1 ml R10 (RPMI 1640 containing
penicillin/streptomycin, 10% fetal calf serum, supple-
mented with 1.0 mg/ml L-glutamine), and live nucleated
cells were enumerated with a nucleocounter (Chemo-
metec, Allerod, Denmark). The range of the nuclecoun-
ter was 5 103–2 106 cells/ml and as several samples
were outside this range, we were unable to convert
proportions to absolute numbers in this study. One-third
of the total number of nucleated cells were aliquoted into
fluorescence-activated cell sorting (FACS) tubes, washed
with Dulbeco’s phosphate-buffered saline (DPBS) and
stained for 20 min with the same panel of antibodies listed
above. Cells were washed and fixed as above, but the lysis
step was omitted.
For intracellular cytokine staining experiments, the
primary stain included anti-CD3 APC (Beckman
Coulter), anti-CD56 PC7 (Beckman Coulter) and
anti-CD16 PB. Cells were incubated in the presence
of GolgiStop (Becton Dickinson), to prevent extracellular
cytokine secretion. Following fixation, cells were
incubated for 15 min, washed, and then permeabilized
and stained with anticytokine antibodies by adding
Reagent B (Life Technologies), anti-CXCL10 PE and
anti-TNF-a AF700. After a further 15 min, cells were
washed with DPBS.
Flow cytometry data were collected on a BD LSRII and
analyzed using FlowJo v10.0.6 (Tree Star, Ashland,
Oregon, USA). At least 5000 CD45þ leukocytes were
collected for each CSF sample, and 3 106 events were
collected for each whole blood specimen. Fluorescence
minus one gating strategies were used to determine
gating boundaries as described [22]. The gating strategy is
shown in Supplementary Figure 1, http://links.lww.
com/QAD/A470.
Statistical analyses
For comparisons between paired specimens, from the
same individual at different time-points, or at the same
time-point but from blood and CSF, a nonparametric
matched-pairs Wilcoxon signed rank test was performed.
This method ignores data points where the pair is
incomplete and, thus, is robust to missing data for the four
individuals for whom samples were unavailable at
completion of antifungal therapy induction. Statisticalhorized reproduction of this article is prohibited.
Co
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(GraphPad, La Jolla, California, USA).Results
Proportions of immunoregulatory natural killer
cells (CD56bright) are expanded in the
cerebrospinal fluid of patients with cryptococcal
meningitis and HIV
Cytolytic and cytokine-secretory roles are performed
by different NK-cell subsets that partially overlap in
function: low expression of CD56 (CD56dim) demarcates
cytolytic NK cells and high expression of CD56
(CD56bright) identifies a cytokine-secreting subset that
is thought to be less mature [23]. At both enrolment and
after completion of antifungal therapy, the CSF was
enriched with CD56bright immunoregulatory NK cells
compared with blood (at enrolment, median 20 vs. 5.4%,
median change D¼ 13.32%, P¼ 0.0004, Fig. 1a), and
had fewer CD56dim NK cells (at enrolment, median 64 vs.
86.1%, median D¼ 20.6%, P<0.0001). The ratio of
CD56bright/CD56dim NK cells was significantly higher in
the CSF compared with blood (Fig. 1b). Neither the
absolute proportions nor the ratio of CD56bright and
CD56dim NK cells was significantly modified following
14 days of antifungal therapy (Fig. 1b).
Expansion of an anergic subset of NK cells with low/
absent CD56 expression (CD56neg) has been observed in
the blood of patients with advanced HIV disease [24].
Notwithstanding the use of classical methods as opposed
to recently described methods using CD7 expression to
enhance specificity of NK-cell gating [25], we did not
observe differences in the proportion of CD56neg NK
cells in the CSF relative to blood (Supplementary Figure
2, http://links.lww.com/QAD/A470). In both blood
and CSF, the median proportion of CD56neg NK cells was
6–7%.
In both blood and cerebrospinal fluid,
immunoregulatory (CD56bright) natural killer
cells and cytolytic (CD56dim) natural killer cells
differed in their expression of CXCR3
To investigate whether immunoregulatory NK cells
differed from cytotoxic NK cells in CSF, we compared
their expression of chemokine receptors. Eisenhardt et al.
[26] recently demonstrated that CXCR3 expression in
extravascular tissues demarcated specific NK-cell subsets
that play a role in infection. Moreover, CXCR3 is the
receptor for proinflammatory chemokines: CXCL9
(MIG), CXCL-10 (IP-10), and CXCL-11 (I-TAC)
[27]. Based on our prior discovery of an increasing
gradient of CXCL-10 from blood to CSF in the
participants of this study [28], we speculated that this
chemokine could mediate chemotaxis of CXCR3-
expressing NK cells into the CNS.pyright © Lippincott Williams & Wilkins. UnauthoAt enrolment in blood, we found a greater proportion of
CD56bright NK cells expressing CXCR3 than CD56dim
NK cells (median 5.4 vs. 2.2%, median D¼ 3.2%,
P<0.0001; Fig. 2a). In contrast, in CSF, a significantly
greater proportion of CD56dim NK cells expressed
CXCR3 than CD56bright NK cells (median 4.2 vs. 2.4%,
median D¼ 1.5%, P¼ 0.0011). Furthermore, we found
that differential CXCR3 expression on CD56bright and
CD56dim NK cells extended to comparisons between
blood and CSF compartments (Fig. 2b and 2c). Among
CD56bright NK cells, the proportion expressing CXCR3
was significantly greater in blood than CSF at enrolment
(median 7.8 vs. 2.1%, median D¼ 4.6%, P¼ 0.0002), but
after 14 days of antifungal therapy, the proportion of
CXCR3pos CD56bright NK cells in blood declined
(median 7.8 vs. 4.8%, median D¼ 2.8%, P¼ 0.009).
By completion of antifungal therapy induction, there was
no difference between blood and CSF in the proportion
of CD56bright NK cells expressing CXCR3 (Fig. 2b). The
proportion of CXCR3pos CD56bright NK cells in CSF did
not change over the period of antifungal therapy induc-
tion.
In contrast, among CD56dim NK cells, the proportion
expressing CXCR3 was significantly greater in CSF than
blood at both enrolment and after completion of anti-
fungal therapy (median 8.6 vs. 3.4%, median D¼ 3.2%
at enrolment, P¼ 0.001; median 7.9 vs. 2.5%, median
D¼ 5.36% at completion of antifungal therapy,
P¼ 0.0005; Fig. 2c). This difference in CXCR3
expression was maintained in CSF over the period of
antifungal therapy induction. However, in blood, the
proportion of CD56dim NK cells expressing CXCR3
declined (median 3.4% at enrolment vs. 2.3% at
completion of antifungal therapy, median D¼ 1.2%,
P¼ 0.03).
The proportion of CXCR3pos, CD56bright, and CD56dim
NK cells in blood following 4 weeks of cART did not
differ from that at completion of antifungal therapy
(Supplementary Figure 3A and B, http://links.lww.com/
QAD/A470).
We also examined expression of CX3CR1 on the various
NK-cell subsets, as CX3CR1-expressing NK cells have
been reported to be involved in modifying autoimmune
CNS disease pathogenesis [29]. At enrolment, in CSF,
there was a higher proportion of CD56dim NK cells
expressing CX3CR1 than CD56bright NK cells (median
10.6 vs. 2.9%, median D¼ 4.8%, P¼ 0.0003), but there
was no difference observed in blood. Both at enrolment
and at completion of antifungal therapy induction, a
larger proportion of CD56bright NK cells in blood
expressed CX3CR1 than those in CSF (median 15.2 vs.
2.8%, median D¼ 14.3%, P¼ 0.001; and median 10.4 vs.
1.4%, median D¼ 6.5%, P¼ 0.009, respectively, Fig. 2b).
The proportion of CX3CR1-expressing CD56dim NK
cells did not differ between blood and CSF regardless ofrized reproduction of this article is prohibited.































































Antifungal therapy induction period
Fig. 1. Absolute proportions and ratios of natural killer-cell subsets at enrolment and completion of induction phase of
antifungal therapy in blood and cerebrospinal fluid. At enrolment and after completion of antifungal therapy induction,
cerebrospinal fluid (CSF) was enriched with CD56bright natural killer (NK) cells, had fewer CD56dim and similar frequencies
of CD56neg NK cells relative to blood (a) and hence the ratio of %CD56bright (immunoregulatory) NK cells to %CD56dim (cytotoxic)
NK cells was higher in CSF than blood at enrolment and after completion of antifungal therapy induction in HIV patients with
cryptococcal meningitis (b). Medians (horizontal lines) and interquartile ranges (whiskers) are shown in each graph. Measurements
in blood denoted by black squares (&) and in CSF denoted by gray circles ( ). NS, not significant.time-point or antifungal therapy. In summary, these data
demonstrate that NK cells differ in expression of CXCR3
and to a lesser extent CX3CR1 chemokine receptors
according to compartment and subset.
Cytotoxic and immunoregulatory natural killer
cells in cerebrospinal fluid were more activated
than natural killer cells in blood
Activation is a necessary precursor of both CD56dim and
CD56bright NK-cell activity. To gain insight into the roleCopyright © Lippincott Williams & Wilkins. Unautof these NK cells in cryptococcal meningitis pathogen-
esis, we examined the proportion of activated cells in each
subset by measuring cell-surface expression of CD69, an
early marker of lymphocyte activation. CD56bright and
CD56dim NK cells in CSF were more activated than
blood NK cells (Fig. 3) at enrolment (median 48.1 vs.
14.3%, median D¼ 37.7%, P<0.0001; and median 54.2
vs. 19.7%, median D¼ 33.3%, P<0.0001, respectively)
and after completion of antifungal therapy induction
(median 52.9 vs. 7.9%, median D¼ 43.2%, P¼ 0.0001;horized reproduction of this article is prohibited.
Co
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Antifungal therapy induction period
Fig. 2. Chemokine receptor 3 expression on all natural killer cells at enrolment and by subset at enrolment and completion of
induction phase of antifungal therapy in blood and cerebrospinal fluid. CXCR3 expression differed by natural killer-cell subset
(CD56bright, CD56dim) and compartment. In blood, at enrolment, the proportion of natural killer (NK) cells expressing CXCR3 was
higher among CD56bright NK cells than among CD56dim NK cells, but the opposite was observed in cerebrospinal fluid (CSF) (a).
The proportion of CD56bright NK cells expressing CXCR3 was significantly higher in blood at enrolment but declined following
antifungal therapy. By completion of antifungal therapy, the proportion in blood was similar to CSF (b). In contrast, the proportion
of CD56dim NK cells expressing CXCR3 was significantly higher in CSF than blood at enrolment and completion of antifungal
therapy (c). Medians (horizontal lines) and interquartile ranges (whiskers) are shown in each graph. Measurements in blood
denoted by black squares (&) and in CSF denoted by gray circles ( ).and median 46.5 vs. 9.95%, median D¼ 31.6%,
P¼ 0.0003, respectively). Although antifungal therapy
did not significantly reduce the proportion of activated
NK cells in blood, or the proportion of activated
CD56bright NK cells in CSF, after completion of
antifungal therapy induction, the proportion of activated
CD56dim NK cells in CSF was significantly reduced
(Fig. 3). After completion of antifungal therapy induc-
tion, the proportion of activated blood NK cells was
positively associated with the plasma HIV viral load
(r¼ 0.65, P¼ 0.007). Consistent with previous reports
[30,31], cART commencement was associated with a
significant decline in the proportions of CD69pos NKpyright © Lippincott Williams & Wilkins. Unauthocells in both CD56bright (median 16.1 vs. 5.7%,
P<0.0001) and CD56dim blood NK-cell subsets (median
10.3 vs. 6.7%, P¼ 0.03, Supplementary Figure 2C and
2D, http://links.lww.com/QAD/A470).
Immunoregulatory natural killer cells in
cerebrospinal fluid expressed higher levels of
CXCL10 and lower levels of tumor necrosis
factor a than natural killer cells in blood prior to
commencing antifungal therapy
Next, we examined whether the chemokine and
cytokine secretion profiles of CD56bright NK cells in
CSF differed from those in blood. CSF levels of therized reproduction of this article is prohibited.
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Antifungal therapy induction period
Fig. 3. Natural killer-cell activation at enrolment and completion of the induction phase of antifungal therapy in blood and
cerebrospinal fluid according to natural killer-cell subset. CD56bright (a) and CD56dim (b) natural killer (NK) cells were more
activated in cerebrospinal fluid (CSF) than in blood at enrolment and completion of antifungal therapy, and activation was only
partially reduced by antifungal therapy induction. Medians (horizontal lines) and interquartile ranges (whiskers) are shown in each
























































Fig. 4. Functional capacity of natural killer cells in blood and
cerebrospinal fluid at enrolment to induction phase anti-
fungal therapy. At enrolment, the proportion of CD56bright
natural killer (NK) cells producing CXCL-10 was higher in
cerebrospinal fluid (CSF) than in blood (a), but the proportion
producing tumor necrosis factor a (TNF-a) was lower in CSF
than in blood (b; n¼5). Results are expressed as the percen-
tage of cytokine-producing cells. Measurements in blood
denoted by black squares (&) and in CSF denoted by gray
circles ( ).chemokine CXCL-10 (IP-10) levels in CSF correlate
directly with neuronal injury in CNS HIV disease [32].
Similarly, the amounts of proinflammatory chemokines
and cytokines, including CXCL-10 and TNF-a,
correlate with clinical outcomes in cryptococcal menin-
gitis and HIV coinfection prior to starting cART [33].
Thus, to quantify differences in functional responses
during HIVand cryptococcal meningitis coinfection, we
compared intracellular cytokine profiles of CXCL-10
and TNF-a in NK cells. We obtained paired blood and
CSF samples at enrolment from five participants and
performed intracellular cytokine staining for CXCL-10
and TNF-a. The proportion of CD56bright NK cells in
CSF expressing CXCL-10 tended to be higher than in
blood (median 57.6 vs. 35.7% median D¼ 19.8%,
P¼ 0.06, Fig. 4). Conversely, the proportion of
CD56bright NK cells in CSF expressing TNF-a tended
to be lower than in blood (median 64.2 vs. 42.3%, median
D¼ 19.84%, P¼ 0.06, Fig. 4).
Cerebrospinal fluid was enriched for nonclassical
monocytes in cryptococcal meningitis prior to
antifungal therapy
NK cells engage in a bidirectional communication with
other innate and adaptive immune cells. During neuro-
inflammation, monocytes are a major cell type that is
recruited to the CNS [34], unlike other tissues that recruit
neutrophils. Therefore, we also evaluated our flow
cytometric data to quantify monocyte subsets in CSF
and blood.
Relative to blood, CSF was enriched for nonclassical
‘proinflammatory’ monocytes at enrolment (median 3.12
vs. 0.78%, median D¼ 1.83%, P¼ 0.001, Fig. 5a).
Correspondingly, the proportion of classical monocytesCopyright © Lippincott Williams & Wilkins. Unautwas lower in CSF than blood (median 30 vs. 64%, median
D¼ 59.8%, P¼ 0.0007). There was also a trend toward a
greater proportion of intermediate monocytes in CSF
than blood (median 18.1 vs. 13.5%, median D¼ 6.5%,
P¼ 0.07).
Antifungal therapy restores proportions of
classical monocytes in cerebrospinal fluid
Comparison of the proportions of the three major
monocyte subsets in CSF at enrolment and after
completion of antifungal therapy demonstrated that the
proportion of classical monocytes significantly increasedhorized reproduction of this article is prohibited.
Co
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(b)
Enrolment Enrolment EnrolmentCompletion Completion Completion
Fig. 5. Monocyte subsets in blood and cerebrospinal fluid at
enrolment and in cerebrospinal fluid only at enrolment and
completion of induction phase of antifungal therapy. The
proportions of nonclassical and intermediate monocytes in
cerebrospinal fluid (CSF) declined following antifungal
therapy induction, whereas the proportion of classical mono-
cytes increased. At enrolment, CSF was enriched with non-
classical monocytes (CD14loCD16hi) and intermediate
monocytes (CD14hiCD16lo), but had significantly lower pro-
portions of classical monocytes (CD14hiiCD16
neg) (a). After
completion of antifungal therapy induction, the proportions of
classical monocyte in CSF were increased and the proportions
of intermediate and nonclassical monocytes in CSF were
reduced (b). Results are expressed as the percentage of total
monocytes. Medians (horizontal lines) and interquartile
ranges (whiskers) are shown in each graph. Measurements
in blood denoted by black squares (&) and in CSF denoted by
gray circles ( ).over time (median 36.1 to 89.5%, median D¼ 23.4%,
P¼ 0.006, Fig. 5b). In contrast, the proportion of
intermediate monocytes significantly decreased (median
13 vs. 2.69%, median D¼ 8.4%, P¼ 0.003), while the
proportion of nonclassical monocytes also declined, but
the difference did not achieve statistical significance
(median 2.78 vs. 3.85%, median D¼ 2.5%, P¼ 0.06).
In comparison, there were no significant differences
between proportions of monocyte subsets in blood at
enrolment and after 14 days of antifungal therapy (data
not shown).pyright © Lippincott Williams & Wilkins. UnauthoDiscussion
Here we assessed NK cells and monocytes in CSF and
blood in patients with HIV-cryptococcal meningitis prior
to and following antifungal therapy induction and cART.
We found that markers of activation and/or function
expressed by NK cells and monocytes were compart-
mentalized in the CNS relative to blood. These findings
suggest that immunoregulatory NK cells and nonclassical
monocytes may play a role in cryptococcal meningitis
pathogenesis. Such changes might contribute to adverse
outcomes after commencing cART, such as cryptococ-
cosis-associated immune reconstitution inflammatory
syndrome (C-IRIS).
Consistent with previous reports of the phenotype of
NK cells in extravascular tissues [2] and during CNS
infections [35], we found a higher proportion of
immunoregulatory (CD56bright) NK cells in CSF than
in blood. Homing of plasmablasts and T cells to the CNS
compartment has been shown to be mediated by CXCR3
[36,37], a receptor for CXCL10. We previously reported
that there was a higher concentration of CXCL-10 in
CSF than in blood in this cohort [28]. CX3CL1 has also
been reported to mediate migration of NK cells to the
CNS during experimental allergic encephalomyelitis
[29]. We observed differences between blood and CSF in
the proportions of both CXCR3pos and CX3CR1pos NK
cells. We, therefore, speculate that the enhanced CXCR3
and/or CX3CR1 expression on CD56bright NK cells in
blood that we observed may have equipped these cells to
enter the CNS compartment in response to a CXCL-10
or CX3CL1 gradient. Tracking chemokine expression on
particular cells to test this hypothesis was beyond the
scope of our work, and remains to be tested.
It is notable that the proportion of CXCR3-expressing
NK cells in the CSF was not affected by antifungal therapy
induction. This subset has been reported to have impaired
cytotoxic and cytokine-secretory capacity in hepatitis C
virus infection [26]. The maintenance of this population
of NK cells in CSF may have implications in the
development of adverse clinical sequelae such as C-IRIS.
Understanding of role of this subset in cryptococcal
meningitis infection will benefit from further study.
We extended previous reports of NK cells in the CNS by
assessing their cytokine profiles and activation status over
time. As predicted, our findings were consistent with
previous reports of decreased activation of NK cells in
blood of HIV-infected adults following cART initiation
and the reduction of HIV burden [30,31]. However, we
observed a partial decline in NK-cell activation only in
the CD56dim subset in the CNS following 2 weeks of
antifungal therapy. We attributed the maintenance of
NK-cell activation in the CNS to either residual
pathogen burden in the CNS [17] or an intrinsic high
threshold for deactivation.rized reproduction of this article is prohibited.
Innate immunity in cryptococcal meningitis Naranbhai et al. 665Our preliminary discovery that immunoregulatory NK
cells secreted more CXCL-10 in CSF than in blood,
suggested that they were preferentially promoting a
proinflammatory environment in the CNS compartment.
The observation that the immunoregulatory NK cells in
CSF produced less TNF-a than in blood may be a result
of interaction with dendritic cells or with cryptococci
[38]. Taking into consideration that NK cells also
generate strong interferon-g responses to Cryptococcus
neoformans [5] and that interferon-g levels in CSF are
one of the leading predictors of clinical outcomes in
cryptococcal meningitis pathogenesis [33], they could be
candidates for immune modulation to improve clinical
outcomes in this disease. However, we examined only a
small number of patients and further studies are needed.
In contrast to NK cells, we observed a rebalancing of
monocyte subsets following antifungal therapy induction.
After 14 days of antifungal therapy, the proportions of
intermediate monocyte subsets in CSF declined, whereas
the proportion of classical monocytes increased. We
attribute this change to differences in functional roles
during clearance of Cryptococcus. Unlike classical mono-
cytes, nonclassical and intermediate monocytes secrete
large amounts of TNF-a and IL-1b, are expanded during
many infectious diseases [39–41], including HIV [42],
and are preferentially recruited to sites of inflammation
[16]. Restoration of monocyte subset distribution with
antifungal therapy suggests that reducing antigen burden
is sufficient to restore monocyte homeostasis in the CNS
compartment.
Although we discovered novel changes in NK cells and
monocyte phenotypes in the CNS compartment during
treated cryptococcal meningitis disease, our findings have
limitations. Because we were unable to quantify absolute
numbers of cells in either CSF or in blood, we cannot
infer whether absolute numbers of specific subsets were
altered. With the exception of antifungal therapy
induction, we were unable to examine the association
between innate immunological events in CSF or blood
and clinical outcomes. Nor can we definitely demonstrate
whether these observations are specific to HIV/crypto-
coccal meningitis or may be observed in other forms of
meningoencephalitis with or without HIV infection. We
examined the effect of cART in only nine patients. Larger
studies are required to establish the clinical relevance
of our findings. Nevertheless, our data provided new
insights into regulation of compartmentalized immune
responses during treated cryptococcal meningitis disease
in adults with advanced HIV.
In summary, our findings suggest that NK cell and
monocyte responses to cryptococci are compartmenta-
lized in patients with cryptococcal meningitis and HIV
coinfection. Furthermore, they highlight a potential role
of immunoregulatory NK cells and different mono-
cyte subsets in cryptococcal meningitis pathogenesis.Copyright © Lippincott Williams & Wilkins. UnautProspective studies of CNS-resident NK cells and
monocytes, and their association with clinical outcomes,
such as C-IRIS, are warranted.Acknowledgements
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